Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug

Submitted by admin on January 27, 2022 - 11:44pm

Source:

BioPharma Dive

News Tags:

Cortexyme

FDA

Alzheimer's disease

Headline:

Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug

snippet:

The Food and Drug Administration has ordered California biotech Cortexyme to stop testing of an experimental Alzheimer's disease drug, notifying the drugmaker in a Jan. 25 letter that it placed a hold on clinical study of the treatment.

Search form

You are here

Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug

Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug